573 related articles for article (PubMed ID: 18097461)
21. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic lymphoma kinase-positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangements.
Shi M; Miron PM; Hutchinson L; Woda BA; Nath R; Cerny J; Yu H
Hum Pathol; 2011 Oct; 42(10):1562-7. PubMed ID: 21497367
[TBL] [Abstract][Full Text] [Related]
23. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
Turner SD; Merz H; Yeung D; Alexander DR
Anticancer Res; 2006; 26(5A):3275-9. PubMed ID: 17094440
[TBL] [Abstract][Full Text] [Related]
24. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
25. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase.
Monaco S; Tsao L; Murty VV; Nandula SV; Donovan V; Oesterheld J; Bhagat G; Alobeid B
Am J Hematol; 2007 Jan; 82(1):59-64. PubMed ID: 16955462
[TBL] [Abstract][Full Text] [Related]
26. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type.
Pileri SA; Pulford K; Mori S; Mason DY; Sabattini E; Roncador G; Piccioli M; Ceccarelli C; Piccaluga PP; Santini D; Leone O; Stein H; Falini B
Am J Pathol; 1997 Apr; 150(4):1207-11. PubMed ID: 9094977
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
29. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma.
Tort F; Campo E; Pohlman B; Hsi E
Hum Pathol; 2004 Aug; 35(8):1038-41. PubMed ID: 15297972
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of anaplastic lymphoma kinase: a patent review.
Milkiewicz KL; Ott GR
Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of ALK signaling for cancer therapy.
Mossé YP; Wood A; Maris JM
Clin Cancer Res; 2009 Sep; 15(18):5609-14. PubMed ID: 19737948
[TBL] [Abstract][Full Text] [Related]
33. ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas.
Gesk S; Gascoyne RD; Schnitzer B; Bakshi N; Janssen D; Klapper W; Martín-Subero JI; Parwaresch R; Siebert R
Leukemia; 2005 Oct; 19(10):1839-40. PubMed ID: 16107887
[No Abstract] [Full Text] [Related]
34. Anaplastic lymphoma kinase in human cancer.
Barreca A; Lasorsa E; Riera L; Machiorlatti R; Piva R; Ponzoni M; Kwee I; Bertoni F; Piccaluga PP; Pileri SA; Inghirami G;
J Mol Endocrinol; 2011 Aug; 47(1):R11-23. PubMed ID: 21502284
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset.
Chan JK
Adv Anat Pathol; 1998 Sep; 5(5):281-313. PubMed ID: 10021895
[No Abstract] [Full Text] [Related]
36. Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence.
Cheuk W; Chan JK
Pathology; 2001 Feb; 33(1):7-12. PubMed ID: 11280613
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma.
Lim MS; Elenitoba-Johnson KS
Mol Cell Proteomics; 2006 Oct; 5(10):1787-98. PubMed ID: 16785248
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.
Coluccia AM; Gunby RH; Tartari CJ; Scapozza L; Gambacorti-Passerini C; Passoni L
Expert Opin Ther Targets; 2005 Jun; 9(3):515-32. PubMed ID: 15948671
[TBL] [Abstract][Full Text] [Related]
40. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma.
Siebert R; Gesk S; Harder L; Steinemann D; Grote W; Schlegelberger B; Tiemann M; Wlodarska I; Schemmel V
Blood; 1999 Nov; 94(10):3614-7. PubMed ID: 10610119
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
